Skip to main content

Oncolytics Biotech Value Stock - Dividend - Research Selection

Oncolytics Biotech

ISIN: CA6823108759, WKN: A2JMW5

Market price date: 15.01.2021
Market price: 3,50 CAD




Oncolytics Biotech Fundamental data and company key figures of the share

Annual reports in CAD
Key figures 16-03-2020
Cash flow
Net operating cash flow -19.906.100
Capital Expenditures -10.905
Free cash flow -19.917.004
Balance sheet
Total Equity -107.894
Liabilities & Shareholders equity 19.657.900
Income statement
Net income -33.122.900
Eps (diluted) -1,500
Diluted shares outstanding 22.081.900
Net sales/revenue 1

Fundamental ratios calculated on: 15-01-2021

Ratios
Key figures 15-01-2021
Cash flow
P/C -3,88
   
P/FC -3,88
Balance sheet
ROI-168,50
ROE-0,55
Income statement
P/E-2,33
Div. Yield0,00%
P/B-716,32
P/S10.000.000,00


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolONC.TO
Market Capitalization59.110.248,00 USD
CountryCanada
IndicesNO INDEX
SectorsBiotechnology
Raw Data SourceIFRS in Millionen CAD
Stock Split2018-05-25,105.0000/1000.0000
Internetwww.oncolyticsbiotech.com


Description of the company

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.oncolyticsbiotech.com